{"id":"NCT01465763","sponsor":"Pfizer","briefTitle":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis","officialTitle":"A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2011-11-07","resultsPosted":"2016-06-07","lastUpdate":"2016-06-07"},"enrollment":614,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"tofacitinib","otherNames":["CP-690,550"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"tofacitinib 10 mg BID","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.","primaryOutcome":{"measure":"Percentage of Participants With Remission at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Tofacitinib 10 mg BID","deltaMin":18.5,"sd":null},{"arm":"Placebo BID","deltaMin":8.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0070"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":178,"countries":["United States","Australia","Austria","Belgium","Canada","Colombia","Croatia","Czechia","Denmark","Estonia","France","Germany","Hungary","Israel","Italy","Japan","Latvia","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["38425446","37560161","37402275","36931693","36739367","36603566","36526796","36506749","36342120","36336750","36271912","36124702","35792493","35648151","35380740","35380664","34614208","34165201","34035832","33684552","33513294","33324993","33127596","32870265","32816215","32794567","32766762","31599001","31077827","30476584","30012431","29850873","29743836","29028981","28467869"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921094&StudyName=A%20Study%20Evaluating%20The%20Efficacy%20And%20Safety%20Of%20CP-690%2C550%20In%20Patients%20With%20Moderate%20To%20Severe%20Ulcerative%20Colitis"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":476},"commonTop":["Nasopharyngitis","Headache","Nausea","Anaemia","Pyrexia"]}}